Keymed Biosciences Reports First Half 2026 Results
Keymed Biosciences announced its interim results for the six months ended June 30, 2026, reporting total revenue of RMB617 million. The company's core product, Kangyueda, generated RMB393 million in sales.
CHENGDU, China – Keymed Biosciences (HKEX: 02162) released its interim financial results on August 19, 2026, for the six-month period ending June 30, 2026. The company reported total revenue of RMB617 million (approximately USD 85 million).
The company's core product, Kangyueda, achieved sales of RMB393 million, marking a 132% year-over-year increase. This growth was attributed to the product's widespread adoption and market presence.
Keymed Biosciences also provided updates on several of its clinical development programs. These updates offer insights into the company's ongoing research and development pipeline and potential future growth drivers.
The biotechnology firm focuses on the development and commercialization of therapeutics, particularly in the fields of oncology and autoimmune diseases. The reported results indicate progress in these strategic areas.